Toxicity From Medication (Endocrine Treatment and Chemotherapy) Given for Breast Cancer Treatment.NCT01563211
Predictive Model of Therapy Outcomes in Breast Cancer Patients
An observational study of Toxicity From Medication (Endocrine Treatment and Chemotherapy) Given for Breast Cancer Treatment., run by Imperial College London at 1 site in United Kingdom.
Trial summary
Patients with breast cancer, who are treated with curative intent, have a combination of surgery (excision of the tumor) and a course of medical therapy (chemotherapy or endocrine treatment). Both treatments are associated with significant side effects. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Toxicity From Medication (Endocrine Treatment and Chemotherapy) Given for Breast Cancer Treatment.
- How many people
- 70 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- Feb 2012to Aug 2014
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Study population: Patients who have newly diagnosed primary breast cancer who will be receiving chemotherapy (FEC and FEC-D regimes only) or endocrine treatment (anastrozole, letrozole or tamoxifen only). All new patients with Breast Cancer are discussed at the multidisciplinary team meeting (MDT) where they will be identified for the study. Patients will be identified by the oncologist and the multidisciplinary team (i.e the existing clinical care team).
Who may be able to join
- Histologically proven breast cancer.
- Female ≥ 18 years of age, no upper age limit.
- Pretreatment haematology and biochemistry values with acceptable limits:
- Haemoglobin (Hb) > 9g/dl
- Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) ≤ 1.5 x ULN
- Serum bilirrubin ≤ 1.5 x ULN
Show all 14Show fewer
- Alkaline phosphatase ≤ 1.5 x ULN
- White blood cell (WBC) count ≥ 3.0 x 109/L and absolute neutrophil count (ANC) ≥ 1.5 x 109/L
- Platelets ≥ 100 x 109/L
- Serum creatinine ≤ 1.5 x ULN
- WHO performance status 0 or 1
- No active or uncontrolled infection
- Written informed consent prior to commencement of specific protocol procedures
- No concomitant medical, psychiatric or geographical problems that might prevent follow up of symptoms according to protocol.
Who cannot join
- Other serious illness or medical condition:
- Congestive heart failure or unstable angina pectoris, previous history of myocardial infarction within 1 year prior to study entry, uncontrolled hypertension or high risk of uncontrolled arrhythmias
- History of significant neurological or psychiatric disorders including psychotic disorders, dementia or seizure that would prohibit the understanding and giving of informed consent
- Active uncontrolled infection
- Active peptic ulcer, unstable diabetes mellitus
- Only cytological proof of malignancy
- Patients not able or willing to give informed consent
- Patients taking medication other than low dose aspirin, antihypertensives or statins.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Predictive Modelling of Short Term Outcomes Following Systemic Neo-adjuvant and Adjuvant Therapy in Breast Cancer Patients
Patients with breast cancer, who are treated with curative intent, have a combination of surgery (excision of the tumor) and a course of medical therapy (chemotherapy or endocrine treatment). Both treatments are associated with significant side effects. Chemotherapy is associated with nausea, vomiting, hair loss and bone marrow suppression, whereas endocrine therapy is associated with arthritis and menopausal symptoms. Patients taking either chemotherapy or endocrine treatment may experience a range of side effects. The range and severity of side effects experienced vary from patient to patient. Little or nothing is known about the reason for this difference.
The aim of the investigators proposal is to develop a pretreatment test to identify patients who are likely to undergo moderate to severe side effects, and therefore help doctors and patients plan and optimize medical therapy. The pretreatment test will be based on identifying a metabolic profile which can differentiate those patients who are likely to have severe or moderate side effects from those with either no or mild side effects. To do this, the investigators will take urine and blood samples from patients before and after the administration of endocrine treatment or chemotherapy and generate metabolic profiles.
Furthermore, the investigators aim to gain an understanding into why side effects experienced between different patients are so variable. To do this the investigators plan to perform cytokine analysis, targeted genetic analysis and pharmaokinetic analysis on blood sample collected from patients before and after treatment has commenced. Patients who have planned surgical excision of tumor and are recommended to receive medical therapy before or after surgery would be invited to join the study. Each patient will be required to make additional visits to the hospital to complete questionnaires regarding side effects experienced and for sample (urine and blood) collection. The investigators plan to recruit 168 patients.
Read the detailed description
Patients with breast cancer are treated with a combination of surgery and medical treatment (either before (neoadjuvant) or after (adjuvant) surgery). Eligible patients will be identified by the oncologist and from the multidisciplinary meeting.
Once eligible patients have been identified they will be informed of the study by their oncologist, and then approached by the research team who will give them a patient information leaflet, discuss the study, answer any questions and ask the patient to sign a consent form if they are would like to participate in the study. The consent form must be signed before any study related procedures are performed.
Patients who have had surgery prior to receiving medical treatment (i.e. patients planned to receive adjuvant treatment, or patients who have a sentinel lymph node biopsy prior to starting neoadjuvant treatment) will have blood and urine samples taken before they have their surgery, at the preassessment surgical appointment.
The week before the patient starts medical therapy (either chemotherapy or endocrine treatment) the patient will need to attend Charing Cross Hospital for the following procedures (this may be an extra visit, depending on hospital appointments):
- To see the study doctor for a medical history and physical examination
- Pulse and blood pressure measurements
- BMI (body mass index) and body fat assessment
- To fill out a quality of life (QOL) questionnaire with research staff
- Routine blood tests (for haematology and biochemistry)
- Blood sample for metabolic profiling and cytokine analysis
- Urine sample for metabolic profiling
- The blood taken will additionally be tested for targeted genetic analysis if the patient has consented for this (as this is optional)
The patient will be asked to return to Charing Cross Hospital 24 hours later after an overnight fast for (this will be an extra visit): • Fasted blood and urine samples for metabolic profiling.
It is important to get fasted samples from patients, as diet influences the metabolic profile. Therefore to try to eliminate diet as a confounder it is important to get a fasted sample. Additionally, at the time of collection of blood and urine samples for metabolic profile analysis patients will be asked when they last ate, what they last ate and any specific dietary preferences/requirements (i.e. vegetarian, gluten free diet).
Further tests differ depending on whether the patient is receiving chemotherapy or endocrine treatment.
Patients receiving chemotherapy have 6 cycles, each cycle last 21 days. There are two types of chemotherapy given for breast cancer which are FEC (6 cycles of 5fluorouracil, epirubicin and cyclophosphamide) or FECD (3 cycles of 5fluorouracil, epirubicin and cyclophosphamide followed by 3 cycles of docetaxel). Patients receiving all types of chemotherapy (FEC and FECD) patients will be required to attend at the following time for procedures are explained below:
- Cycle 1, day 2
- 24 hours after the patient received their chemotherapy treatment we will take urine and blood samples for metabolic profiling, and blood samples for routine blood tests (haematology and biochemistry) and cytokine analysis.
- At this time the patient will also be asked to fill out 2 questionnaires with research staff - the first will be adverse effects experienced (questions from CTCAEv4.0), and the second will be a QOL questionnaire.
- This will be an extra visit.
- Cycle 2, day 1
- Prior to receiving their next cycle of chemotherapy urine and blood samples will be taken for metabolic profiling. Blood samples will be taken for routine tests (haematology and biochemistry) and for cytokine analysis.
- Two questionnaires (questionnaire based on adverse effects experienced and QOL questionnaire) will be completed with research staff.
- A blood sample will be taken after 10 minutes chemotherapy infusion has finished. Pharmacokinetic analysis for 5FU will be conducted on this sample. If possible the sample will be taken from the cannula through which the chemotherapy medication was administered (the first 10mls will need to be discarded to avoid contamination).
- This will not be an extra visit if there has been no change to planned This will not be an extra visit if there has been no change to planned treatment schedule. If patients have consented for optional pharmacokinetic analysis the following sample will also be taken.
- Cycle 2, day 1 (optional assessment)
- Three blood samples will be taken during the following 4 hours for pharmacokinetic analysis of cylophosphamide and epirubicin. If possible all samples will be taken from the cannula through which the chemotherapy was administered.
- Cycle 2, day 2 (optional assessment) o A blood sample will be taken 24 hours after the chemotherapy was given for pharmacokinetic analysis of cyclophosphamide.
- Cycle 2, day 3 (optional assessment)
- A blood sample will be taken 48 hours after the chemotherapy was given for pharmacokinetic analysis of epirubicin.
- Cycle 6, day 21
- Two questionnaires (questionnaire based on adverse effects experienced and QOL questionnaire) will be completed with research staff.
- BMI (body mass index) and body fat assessment.
- This will be an extra visit.
If patients are on FECD chemotherapy, they will attend at the above time points, but they will additionally be asked to attend after their docetaxel has commenced. This is required to test whether docetaxel has a different reaction in the body to the previous chemotherapy given. Patients will be asked to attend at the following time points for the following procedures:
- Cycle 4, day 2
- 24 hours after the patient received their chemotherapy treatment we will take urine and blood samples for metabolic profiling, and blood samples for routine blood tests (haematology and biochemistry) and cytokine analysis.
- Two questionnaires (questionnaire based on adverse effects experienced and QOL questionnaire) will be completed with research staff
- This will be an extra visit
- Cycle 5, day 1
- Prior to receiving their next cycle of chemotherapy urine and blood samples will be taken for metabolic profiling. Blood samples will be taken for routine tests (haematology and biochemistry) and for cytokine analysis.
- Two questionnaires (questionnaire based on adverse effects experienced and QOL questionnaire) will be completed with research staff.
- This will not be an extra visit if there has been no change to planned treatment schedule.
If patients have consented for optional pharmacokinetic analysis the following sample will also be taken.
- Cycle 5, day 1
- A blood sample will be taken at the end of the chemotherapy infusion and 6 hours after the infusion completed. If possible the blood samples will be taken from the cannula (the first 10mls taken from the cannula will need to be discarded to avoid contamination).
Patients receiving endocrine treatment will be asked to attend at the following time points after starting treatment for procedures listed below, in addition to baseline assessments described above:
- Day 2
- Urine and blood samples for metabolic profiling. Blood samples for routine tests (haematology and biochemistry) and cytokine analysis.
- This will be an extra visit
- Day 21
- Two questionnaires (questionnaire based on adverse effects experienced and QOL questionnaire) will be completed with research staff.
- Urine and blood samples for metabolic profiling. Blood samples for routine tests (haematology and biochemistry) and cytokine analysis.
- This will be an extra visit
- At 5 months
- Two questionnaires (questionnaire based on adverse effects experienced and QOL questionnaire) will be completed with research staff.
- BMI (body mass index) and body fat assessment.
- A blood sample for pharmacokinetic analysis
- This will be an extra visit
All procedures and interviews will be conducted at Charing Cross Hospital. All patients will be enrolled in the study for 5 months. However, for patients receiving chemotherapy, if there has been a change in treatment schedule by the oncologist the time the patient will spend in the study will be increased in accordance with changes made to treatment schedule (i.e. if cycle 4 (docetaxel) is started 1 week late, then the time in the study will be 5 months and 1 week).
For patients receiving neoadjuvant treatment (chemotherapy or endocrine treatment before surgery) we will look at imaging and pathology reports to establish how the tumour has responded to treatment.
We aim to recruit 168 patients, 84 receiving endocrine therapy (either an oestrogen receptor antagonist or aromatase inhibitor) and 84 receiving cytotoxic chemotherapy (FEC or FECD).
The study will be conducted in 5 phases:
- Patient recruitment and collection of samples (months 112)
- H NMR spectroscopic analysis and UPLMS analysis of samples (months 718)
- Mathematical modelling of the data (months 120)
- Structural identification of candidate biomarkers (months 1822)
- Write up of results and guidelines (months 2024)
The results will be analysed and published (in both presentations and a peer reviewed journal) at the end of the study. No patient identifiable information will be present in these publications. As all tests are carried out for research purposes and will be of no direct benefit to patients participating in this study, there are no plans to inform patients of their individual results. Patients will be informed of the overall results from the study that may result in a publication.
- Conditions
- Toxicity From Medication (Endocrine Treatment and Chemotherapy) Given for Breast Cancer Treatment.
- Keywords
- breast cancer therapy, toxicity, side effect profile
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients receiving endocrine treatment for breast cancer | Patients who are treated with tamoxifen, anastrozole or letrozole before or after surgery for breast cancer. | |
| Patients receiving chemotherapy for breast cancer | Patients receiving FEC (5-FU, cyclophosphamide, epiribicin) or FEC-D (FEC for 3 cycles, followed by 3 cycles of docetaxel). |
What is being measured
The primary outcome is the main question the study is designed to answer.
The primary outcome measure for the study is to determine the relationship between metabonomics spectrum and side effects from chemotherapy and endocrine therapy for patients receiving treatment for breast cancer.
To identify a pre-treatment metabolic profile to predict patients who will experience moderate to severe side effects.
Measured: 2 years
Secondary outcomes (5)
Conduct pharmokinetic analysis of drugs administered and determine relationship between pharmacokinetics and severity of side effects experienced.
Measure pharmokinetics of each drug to try and ascertain underlying reasons for differences in toxicity.
Measured: 2 years
Conduct cytokine analysis pre and post treatment, to determine relationship with severity of side effects experienced.
Measured: 2 years
Conduct targeted genetic analysis to determine relationship with severity of side effects experienced.
To identify known SNPs implicated in toxicity to metabolic profile/biomarkers found.
Measured: 2 years
To find underlying mechanism to explain the interpatient variability in severity of side effects experienced using above techniques (i.e. metabolic profile, pharmacokinetic analysis, cytokine analysis and targeted genetic analysis).
Measured: 2 years
To identify a biomarker based on metabnomic profiling for response to treatment for those receiving neoadjuvant treatment.
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Mar 2012 (estimated)
- Study startFeb 2012
- Primary completionAug 2014
- Study completionAug 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Toxicity From Medication (Endocrine Treatment and Chemotherapy) Given for Breast Cancer Treatment.Studies of the same condition, open and under way.
- More trials run by Imperial College LondonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 70 participants (actual)
Sponsor and investigators
- Lead sponsor
- Imperial College London
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Charles Coombes, Principal investigator, Imperial College London
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01563211
- Sponsor's protocol ID
- 72393/271478/14/611
- Other IDs
- 11-LO-1644
- Status last verified
- Mar 2012
- First submitted
- 25 Jan 2012
- Last updated
- 26 Mar 2015
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Mar 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Predictive Modelling of Short Term Outcomes Following Systemic Neo-adjuvant and Adjuvant Therapy in Breast Cancer Patients
- ClinicalTrials.gov ID
- NCT01563211
- Acronym / sponsor ID
- 72393/271478/14/611
- Conditions
- Toxicity From Medication (Endocrine Treatment and Chemotherapy) Given for Breast Cancer Treatment.
- Keywords
- breast cancer therapy, toxicity, side effect profile
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 70 participants (actual)
- Lead sponsor
- Imperial College LondonUniversity, hospital or other
- Study start
- Feb 2012
- Primary completion
- Aug 2014 (actual)
- Study completion
- Aug 2014 (actual)
- First posted
- 26 Mar 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients with breast cancer, who are treated with curative intent, have a combination of surgery (excision of the tumor) and a course of medical therapy (chemotherapy or endocrine treatment). Both treatments are associated with significant side effects. Chemotherapy is associated with nausea, vomiting, hair loss and bone marrow suppression, whereas endocrine therapy is associated with arthritis and menopausal symptoms. Patients taking either chemotherapy or endocrine treatment may experience a range of side effects. The range and severity of side effects experienced vary from patient to patient. Little or nothing is known about the reason for this difference.
The aim of the investigators proposal is to develop a pretreatment test to identify patients who are likely to undergo moderate to severe side effects, and therefore help doctors and patients plan and optimize medical therapy. The pretreatment test will be based on identifying a metabolic profile which can differentiate those patients who are likely to have severe or moderate side effects from those with either no or mild side effects. To do this, the investigators will take urine and blood samples from patients before and after the administration of endocrine treatment or chemotherapy and generate metabolic profiles.
Furthermore, the investigators aim to gain an understanding into why side effects experienced between different patients are so variable. To do this the investigators plan to perform cytokine analysis, targeted genetic analysis and pharmaokinetic analysis on blood sample collected from patients before and after treatment has commenced. Patients who have planned surgical excision of tumor and are recommended to receive medical therapy before or after surgery would be invited to join the study. Each patient will be required to make additional visits to the hospital to complete questionnaires regarding side effects experienced and for sample (urine and blood) collection. The investigators plan to recruit 168 patients.
Detailed description
Patients with breast cancer are treated with a combination of surgery and medical treatment (either before (neoadjuvant) or after (adjuvant) surgery). Eligible patients will be identified by the oncologist and from the multidisciplinary meeting.
Once eligible patients have been identified they will be informed of the study by their oncologist, and then approached by the research team who will give them a patient information leaflet, discuss the study, answer any questions and ask the patient to sign a consent form if they are would like to participate in the study. The consent form must be signed before any study related procedures are performed.
Patients who have had surgery prior to receiving medical treatment (i.e. patients planned to receive adjuvant treatment, or patients who have a sentinel lymph node biopsy prior to starting neoadjuvant treatment) will have blood and urine samples taken before they have their surgery, at the preassessment surgical appointment.
The week before the patient starts medical therapy (either chemotherapy or endocrine treatment) the patient will need to attend Charing Cross Hospital for the following procedures (this may be an extra visit, depending on hospital appointments):
- To see the study doctor for a medical history and physical examination
- Pulse and blood pressure measurements
- BMI (body mass index) and body fat assessment
- To fill out a quality of life (QOL) questionnaire with research staff
- Routine blood tests (for haematology and biochemistry)
- Blood sample for metabolic profiling and cytokine analysis
- Urine sample for metabolic profiling
- The blood taken will additionally be tested for targeted genetic analysis if the patient has consented for this (as this is optional)
The patient will be asked to return to Charing Cross Hospital 24 hours later after an overnight fast for (this will be an extra visit): • Fasted blood and urine samples for metabolic profiling.
It is important to get fasted samples from patients, as diet influences the metabolic profile. Therefore to try to eliminate diet as a confounder it is important to get a fasted sample. Additionally, at the time of collection of blood and urine samples for metabolic profile analysis patients will be asked when they last ate, what they last ate and any specific dietary preferences/requirements (i.e. vegetarian, gluten free diet).
Further tests differ depending on whether the patient is receiving chemotherapy or endocrine treatment.
Patients receiving chemotherapy have 6 cycles, each cycle last 21 days. There are two types of chemotherapy given for breast cancer which are FEC (6 cycles of 5fluorouracil, epirubicin and cyclophosphamide) or FECD (3 cycles of 5fluorouracil, epirubicin and cyclophosphamide followed by 3 cycles of docetaxel). Patients receiving all types of chemotherapy (FEC and FECD) patients will be required to attend at the following time for procedures are explained below:
- Cycle 1, day 2
- 24 hours after the patient received their chemotherapy treatment we will take urine and blood samples for metabolic profiling, and blood samples for routine blood tests (haematology and biochemistry) and cytokine analysis.
- At this time the patient will also be asked to fill out 2 questionnaires with research staff - the first will be adverse effects experienced (questions from CTCAEv4.0), and the second will be a QOL questionnaire.
- This will be an extra visit.
- Cycle 2, day 1
- Prior to receiving their next cycle of chemotherapy urine and blood samples will be taken for metabolic profiling. Blood samples will be taken for routine tests (haematology and biochemistry) and for cytokine analysis.
- Two questionnaires (questionnaire based on adverse effects experienced and QOL questionnaire) will be completed with research staff.
- A blood sample will be taken after 10 minutes chemotherapy infusion has finished. Pharmacokinetic analysis for 5FU will be conducted on this sample. If possible the sample will be taken from the cannula through which the chemotherapy medication was administered (the first 10mls will need to be discarded to avoid contamination).
- This will not be an extra visit if there has been no change to planned This will not be an extra visit if there has been no change to planned treatment schedule. If patients have consented for optional pharmacokinetic analysis the following sample will also be taken.
- Cycle 2, day 1 (optional assessment)
- Three blood samples will be taken during the following 4 hours for pharmacokinetic analysis of cylophosphamide and epirubicin. If possible all samples will be taken from the cannula through which the chemotherapy was administered.
- Cycle 2, day 2 (optional assessment) o A blood sample will be taken 24 hours after the chemotherapy was given for pharmacokinetic analysis of cyclophosphamide.
- Cycle 2, day 3 (optional assessment)
- A blood sample will be taken 48 hours after the chemotherapy was given for pharmacokinetic analysis of epirubicin.
- Cycle 6, day 21
- Two questionnaires (questionnaire based on adverse effects experienced and QOL questionnaire) will be completed with research staff.
- BMI (body mass index) and body fat assessment.
- This will be an extra visit.
If patients are on FECD chemotherapy, they will attend at the above time points, but they will additionally be asked to attend after their docetaxel has commenced. This is required to test whether docetaxel has a different reaction in the body to the previous chemotherapy given. Patients will be asked to attend at the following time points for the following procedures:
- Cycle 4, day 2
- 24 hours after the patient received their chemotherapy treatment we will take urine and blood samples for metabolic profiling, and blood samples for routine blood tests (haematology and biochemistry) and cytokine analysis.
- Two questionnaires (questionnaire based on adverse effects experienced and QOL questionnaire) will be completed with research staff
- This will be an extra visit
- Cycle 5, day 1
- Prior to receiving their next cycle of chemotherapy urine and blood samples will be taken for metabolic profiling. Blood samples will be taken for routine tests (haematology and biochemistry) and for cytokine analysis.
- Two questionnaires (questionnaire based on adverse effects experienced and QOL questionnaire) will be completed with research staff.
- This will not be an extra visit if there has been no change to planned treatment schedule.
If patients have consented for optional pharmacokinetic analysis the following sample will also be taken.
- Cycle 5, day 1
- A blood sample will be taken at the end of the chemotherapy infusion and 6 hours after the infusion completed. If possible the blood samples will be taken from the cannula (the first 10mls taken from the cannula will need to be discarded to avoid contamination).
Patients receiving endocrine treatment will be asked to attend at the following time points after starting treatment for procedures listed below, in addition to baseline assessments described above:
- Day 2
- Urine and blood samples for metabolic profiling. Blood samples for routine tests (haematology and biochemistry) and cytokine analysis.
- This will be an extra visit
- Day 21
- Two questionnaires (questionnaire based on adverse effects experienced and QOL questionnaire) will be completed with research staff.
- Urine and blood samples for metabolic profiling. Blood samples for routine tests (haematology and biochemistry) and cytokine analysis.
- This will be an extra visit
- At 5 months
- Two questionnaires (questionnaire based on adverse effects experienced and QOL questionnaire) will be completed with research staff.
- BMI (body mass index) and body fat assessment.
- A blood sample for pharmacokinetic analysis
- This will be an extra visit
All procedures and interviews will be conducted at Charing Cross Hospital. All patients will be enrolled in the study for 5 months. However, for patients receiving chemotherapy, if there has been a change in treatment schedule by the oncologist the time the patient will spend in the study will be increased in accordance with changes made to treatment schedule (i.e. if cycle 4 (docetaxel) is started 1 week late, then the time in the study will be 5 months and 1 week).
For patients receiving neoadjuvant treatment (chemotherapy or endocrine treatment before surgery) we will look at imaging and pathology reports to establish how the tumour has responded to treatment.
We aim to recruit 168 patients, 84 receiving endocrine therapy (either an oestrogen receptor antagonist or aromatase inhibitor) and 84 receiving cytotoxic chemotherapy (FEC or FECD).
The study will be conducted in 5 phases:
- Patient recruitment and collection of samples (months 112)
- H NMR spectroscopic analysis and UPLMS analysis of samples (months 718)
- Mathematical modelling of the data (months 120)
- Structural identification of candidate biomarkers (months 1822)
- Write up of results and guidelines (months 2024)
The results will be analysed and published (in both presentations and a peer reviewed journal) at the end of the study. No patient identifiable information will be present in these publications. As all tests are carried out for research purposes and will be of no direct benefit to patients participating in this study, there are no plans to inform patients of their individual results. Patients will be informed of the overall results from the study that may result in a publication.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Patients receiving endocrine treatment for breast cancer | – | –Patients who are treated with tamoxifen, anastrozole or letrozole before or after surgery for breast cancer. |
| Patients receiving chemotherapy for breast cancer | – | –Patients receiving FEC (5-FU, cyclophosphamide, epiribicin) or FEC-D (FEC for 3 cycles, followed by 3 cycles of docetaxel). |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients who have newly diagnosed primary breast cancer who will be receiving chemotherapy (FEC and FEC-D regimes only) or endocrine treatment (anastrozole, letrozole or tamoxifen only). All new patients with Breast Cancer are discussed at the multidisciplinary team meeting (MDT) where they will be identified for the study. Patients will be identified by the oncologist and the multidisciplinary team (i.e the existing clinical care team).
Key inclusion criteria (14 listed)
- Histologically proven breast cancer.
- Female ≥ 18 years of age, no upper age limit.
- Pretreatment haematology and biochemistry values with acceptable limits:
- Haemoglobin (Hb) > 9g/dl
- Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) ≤ 1.5 x ULN
Key exclusion criteria (8 listed)
- Other serious illness or medical condition:
- Congestive heart failure or unstable angina pectoris, previous history of myocardial infarction within 1 year prior to study entry, uncontrolled hypertension or high risk of uncontrolled arrhythmias
- History of significant neurological or psychiatric disorders including psychotic disorders, dementia or seizure that would prohibit the understanding and giving of informed consent
- Active uncontrolled infection
- Active peptic ulcer, unstable diabetes mellitus
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
The primary outcome measure for the study is to determine the relationship between metabonomics spectrum and side effects from chemotherapy and endocrine therapy for patients receiving treatment for breast cancer.
Time frame: 2 years
To identify a pre-treatment metabolic profile to predict patients who will experience moderate to severe side effects.
5 secondary outcomes
Conduct pharmokinetic analysis of drugs administered and determine relationship between pharmacokinetics and severity of side effects experienced.
Time frame: 2 years
Conduct cytokine analysis pre and post treatment, to determine relationship with severity of side effects experienced.
Time frame: 2 years
Conduct targeted genetic analysis to determine relationship with severity of side effects experienced.
Time frame: 2 years
To find underlying mechanism to explain the interpatient variability in severity of side effects experienced using above techniques (i.e. metabolic profile, pharmacokinetic analysis, cytokine analysis and targeted genetic analysis).
Time frame: 2 years
To identify a biomarker based on metabnomic profiling for response to treatment for those receiving neoadjuvant treatment.
Time frame: 2 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Mar 2015.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Charles Coombes principal investigator
Imperial College London
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Toxicity From Medication (Endocrine Treatment and Chemotherapy) Given for Breast Cancer Treatment., run by Imperial College London at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Mar 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The primary outcome measure for the study is to determine the relationship between metabonomics spectrum and side effects from chemotherapy and endocrine therapy for patients receiving treatment for breast cancer. (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Mar 2015.